We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Less than a week after the FDA halted Juno Therapeutics’ Phase 2 cancer trial over three patient deaths, the agency has given the company the go-ahead to resume the trial. Read More
Less than a week after the FDA halted Juno Therapeutics’ Phase 2 cancer trial over three patient deaths, the agency has given the company the go-ahead to resume the trial. Read More
The FDA and the European Medicines Agency have formed a new working group focusing on incorporating patient perspectives into drug development, evaluation and post-marketing activities. Read More